Meet the Team
The Actigen Management Team
Michael Braunagel
Managing Director
As Actigen’s Managing Director, Michael has led the organisation since 2016. He steers the Company’s commercial strategy and oversees all product development, intellectual property, collaborations and financing. Having started as a laboratory scientist, he has many years of experience in the biotechnology sector including positions at the German Cancer Research Centre and at Affitech Research, Actigen’s parent company.
Stig Jarle Pettersen
Financial Advisor and Board Member
Stig Jarle has extensive experience in all areas of finance, and company strategy, working at a strategic level primarily in the international pharmaceutical, aviation, and fish farming industries. He is a director of Actigen, financial advisor for Affitech Research AS (Actigen’s parent company), and an executive board member of Affitech A/S.
Alex Duncan
Board Member
Alex Duncan has many years of leadership experience in the biopharmaceutical industry, working globally in scientific and strategic roles, and has been a director of Actigen since 2012. Alex is currently Chief Scientific Officer for Walden Biosciences, having previously worked across a wide range of therapy areas for companies such as Agenus, Affitech A/S, AstraZeneca, and Cambridge Antibody Technology.
Kamilla Rolsted
Business Development
Kamilla is a highly experienced business development professional, with an in-depth understanding of business strategy and financing. She has worked with a wide range of organisations, including Bionor Pharma and Zealand Pharma, and also supports several smaller companies, academia and entrepreneurial initiatives.
Ro Gardner
Operations Communications
Ro has a scientific background and has spent her career working in both communications and operational roles. She has been working with Actigen since 2013, having also worked with a wide range of organisations in the life sciences sector, including Cambridge Antibody Technology, the BioIndustry Association, the Institute for Food Research, MedImmune, Agenus, and Microbiotica.
MPS II Programme Advisors
Peter Bach
Programme Lead
Peter’s global pharmaceutical and biopharmaceutical background provides the programme with a vast amount of development experience and leadership, gained from taking numerous therapeutic programmes in a variety of diseases from discovery to market approval. He has previously worked with a wide range of organisations, including MedImmune, CellTech, and Charles River.
Julie Foulkes
Regulatory Affairs Advisor
Julie brings her substantial regulatory affairs experience to the programme, providing key inputs for addressing regulatory challenges as well as providing strategic and operational support to the team. She has worked with a wide range of companies including start-up and global companies, across a wide range of therapeutics, including treatments for rare and orphan diseases, providing support from the development phase through to life cycle management.
Allison Morgan
Clinical Research Advisor
Allison is a highly experienced clinical research professional, providing expert guidance to the programme’s clinical development strategy. Allison has supported a variety of clinical programmes from inception through to regulatory submission, working across a range of therapeutic areas, including paediatric rare and orphan diseases, and with a number of organisations, such as Prosensa Therapeutics, UCB Pharma, and Abbott Laboratories.
John Powell
Pharmaceutical Physician
John is the programme’s medical advisor, bringing his many years of biopharmaceutical industry experience and his expert medical knowledge to the team. Having worked initially within the National Health Service, John has provided medical leadership for clinical programmes run by a variety of pharmaceutical and biopharmaceutical companies, such as Napp, Cambridge Antibody Technology, PanGenetics, and Circassia.
Peter Treasure
Statistician
Peter is a statistician working both in academia and pharmaceutical development. He has many years’ experience of designing and analysing clinical trials, of developing diagnostic tests, and of serving on data safety monitoring committees.